Department of Biopathology, Centre Léon Bérard, Lyon, France; Department of Research, University of Lyon, Université Claude Bernard Lyon 1, Cancer Research Centre of Lyon, Lyon, France.
Department of Biopathology, Centre Léon Bérard, Lyon, France; Department of Research, University of Lyon, Université Claude Bernard Lyon 1, Cancer Research Centre of Lyon, Lyon, France.
Mod Pathol. 2023 Nov;36(11):100286. doi: 10.1016/j.modpat.2023.100286. Epub 2023 Jul 19.
Fusion genes involving homologs of protein kinase C (PKC) have been identified in a variety of tumors. We report the clinical and histologic presentation of 51 cutaneous melanocytic neoplasms with a PKC fusion gene (involving PRKCA in 35 cases, PRKCB in 15 cases, and PRKCG in a single case). Most tumors were in young adults (median age, 29.5 years; range, 1-73 years) but some presented in newborns. Histologically, 42 tumors were classified as benign, presenting predominantly as biphasic dermal proliferation (88%) with nests of small melanocytes surrounded by fibrosis with haphazardly arranged spindled and dendritic melanocytes, resembling those reported as "combined blue nevi." Most tumors (60%) were heavily pigmented and in 15%, hyperpigmented epithelioid melanocytes were present at the dermoepidermal junction. Two lesions were paucicellular and showed marked sclerosis. Three tumors, including 2 proliferating nodules, were considered intermediate grade. Six tumors had sheets of atypical melanocytes infiltrating the dermis and were classified as melanomas. Two of the melanomas displayed loss of BAP1 nuclear expression. The median follow-up time was 12 months, with 1 patient alive with metastatic disease and 1 dying of their melanoma. These results suggest that melanocytic tumors with PKC fusion genes have characteristic histopathologic features, which are more similar to blue nevi than to pigmented epithelioid melanocytomas. As is the case with GNA-mutated blue nevi, they can progress to melanomas via BAP1 inactivation and metastasize.
涉及蛋白激酶 C(PKC)同源物的融合基因已在多种肿瘤中被鉴定出来。我们报告了 51 例具有 PKC 融合基因的皮肤黑素细胞肿瘤(涉及 PRKCA 的 35 例,PRKCB 的 15 例,PRKCG 的 1 例)的临床和组织学表现。大多数肿瘤发生在年轻人中(中位年龄 29.5 岁;范围 1-73 岁),但有些发生在新生儿中。组织学上,42 例肿瘤被分类为良性,主要表现为双相真皮增殖(88%),伴有小黑素细胞巢,周围有纤维化,纺锤形和树突状黑素细胞排列杂乱,类似于报告的“混合性蓝痣”。大多数肿瘤(60%)色素沉着严重,在 15%的肿瘤中,在表皮真皮交界处存在色素增加的上皮样黑素细胞。2 个病变细胞稀少,表现出明显的硬化。3 个肿瘤,包括 2 个增生性结节,被认为是中级别的。6 个肿瘤的真皮内有片状不典型黑素细胞浸润,被分类为黑色素瘤。其中 2 个黑色素瘤显示 BAP1 核表达缺失。中位随访时间为 12 个月,1 例患者有转移性疾病存活,1 例患者死于黑色素瘤。这些结果表明,具有 PKC 融合基因的黑素细胞肿瘤具有特征性的组织病理学特征,与蓝痣更为相似,而与色素性上皮样黑素细胞瘤不同。与 GNA 突变的蓝痣一样,它们可以通过 BAP1 失活和转移进展为黑色素瘤。